Recent Company News

• 06:52 AM ET Nov 03, 2026
  

  Technical Reactions to RDY Trends in Macro Strategies

• 09:34 AM ET Nov 02, 2026
  

  Dr. Reddy's Laboratories announces FDA tentative approval of lenacapavir for HIV PrEP ($14.17, 0.00)

• 06:54 AM ET Oct 28, 2026
  

  NMPA accepts submission of Junshi Biosciences's marketing application for JS001sc to be combined with disitamab vedotin for urothelial carcinoma with HER2 expression (HK$16.06, 0.00)

• 06:49 AM ET Oct 28, 2026
  

  NMPA gives routine approval to Junshi Biosciences's JS001 for locally advanced or metastatic urothelial carcinoma (HK$16.06, 0.00)

• 11:54 PM ET Oct 27, 2026
  

  Shanghai Junshi Biosciences reports final analysis results from Phase 3 NEOTORCH study presented at ESMO (HK$16.22, +0.54)

• 10:09 PM ET Oct 26, 2026
  

  Dr. Reddy's Laboratories upgraded to buy from neutral at PhillipCapital (India) (INR 1303.00, 0.00)

• 08:26 AM ET Oct 26, 2026
  

  StreetAccount Summary - US Pre-market trading

• 04:30 AM ET Oct 26, 2026
  

  Dr. Reddy's Laboratories upgraded to buy from hold at Systematix Institutional Research

• 03:06 AM ET Oct 26, 2026
  

  Dr. Reddy's Laboratories upgraded to accumulate from reduce at Elara Capital (INR 1300.00, +75.50)

• 02:44 AM ET Oct 26, 2026
  

  StreetAccount Summary - Trading higher/lower: India mid-day